- Home
- TNK vs NRIX Comparison
TNK vs NRIX Comparison
Compare TNK & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNK
- NRIX
- Stock Information
- Founded
- TNK 2007
- NRIX 2009
- Country
- TNK Bermuda
- NRIX United States
- Employees
- TNK N/A
- NRIX N/A
- Industry
- TNK Marine Transportation
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- TNK Consumer Discretionary
- NRIX Health Care
- Exchange
- TNK Nasdaq
- NRIX Nasdaq
- Market Cap
- TNK 1.3B
- NRIX 1.1B
- IPO Year
- TNK 2007
- NRIX 2020
- Fundamental
- Price
- TNK $38.28
- NRIX $11.88
- Analyst Decision
- TNK Buy
- NRIX Strong Buy
- Analyst Count
- TNK 3
- NRIX 17
- Target Price
- TNK $62.00
- NRIX $30.82
- AVG Volume (30 Days)
- TNK 354.0K
- NRIX 879.4K
- Earning Date
- TNK 05-08-2025
- NRIX 04-14-2025
- Dividend Yield
- TNK 2.60%
- NRIX N/A
- EPS Growth
- TNK N/A
- NRIX N/A
- EPS
- TNK 11.63
- NRIX N/A
- Revenue
- TNK $1,229,336,000.00
- NRIX $54,549,000.00
- Revenue This Year
- TNK N/A
- NRIX N/A
- Revenue Next Year
- TNK N/A
- NRIX $3.20
- P/E Ratio
- TNK $3.33
- NRIX N/A
- Revenue Growth
- TNK N/A
- NRIX N/A
- 52 Week Low
- TNK $35.23
- NRIX $11.38
- 52 Week High
- TNK $74.20
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- TNK 47.08
- NRIX 29.28
- Support Level
- TNK $37.47
- NRIX $12.20
- Resistance Level
- TNK $39.01
- NRIX $13.10
- Average True Range (ATR)
- TNK 1.23
- NRIX 0.77
- MACD
- TNK 0.15
- NRIX -0.01
- Stochastic Oscillator
- TNK 60.65
- NRIX 14.33
About TNK Teekay Tankers Ltd.
Teekay Tankers Ltd is a provider of marine services to the global oil and natural gas industries and an operator of medium-sized oil tankers. The company operates in two segments: tanker and ship-to-ship transfer. The vast majority of its revenue comes from the tanker segment, which consists of crude oil and product tankers for different contracts.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.